Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...

Objective To estimate the incidence of herpes zoster (HZ) and the incremental healthcare resource utilisation (HRU) and costs ...

Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been ...

Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological change of renal injury in LN. Enhanced histone deacetylase 3 (HDAC3) ...

Case 1: A 35-year-old female with SLE and planning IVF pregnancy In October 2024 a 35-year-old female with systemic lupus erythematosus (SLE) was reviewed for planning of in vitro fertilization (IVF) ...

22 Historical aspects of B-cell depletion in SLE (8 October, 2025) ...

Objective SLE affects multiple organs and is associated with increased mortality and organ damage. While treatment recommendations for non-renal SLE stratify by disease activity, no standard approach ...

Objectives To evaluate the diagnostic and prognostic performance of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in SLE and to integrate these biomarkers into an ...

Objectives To evaluate the Systemic Lupus International Collaborating Clinics-Frailty Index (SLICC-FI) as a predictor of hospitalisations in patients with SLE from a Latin American cohort. Methods ...

Objective Patients with SLE have a well-known increased risk of major comorbidities, although they are also very heterogeneous in terms of the prevalence of comorbid conditions. The relationships of ...

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...

Objectives To achieve consensus on domains of active disease for inclusion in a novel outcome measure for SLE randomised controlled trials (RCTs), the Treatment Response Measure for SLE (TRM-SLE).